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To the Editor: Debate has emerged in South African health
research circles regarding the appropriate remuneration for
individuals participating in research studies.
Most international and national guidelines on health
research ethics vaguely warn against unfair inducement of
individuals to participate in research but are otherwise silent
on this issue. The most comprehensive guideline referring to
participant remuneration is that of the Council for International
Organisations of Medical Sciences (CIOMS).1 This document
has been developed in conjunction with the World Health
Organisation (WHO) and refers specifically to research in
developing countries. Guidelines 4 (1993 version) and 11 (2002
revised draft) refer to ‘inducement to participate’.
Guideline 4 states, inter alia, that ‘subjects may be paid for
inconvenience and time spent, and should be reimbursed for
expenses incurred, in connection with their participation in
research’. Guideline 11 states, inter alia, that  ‘subjects may be
paid or otherwise rewarded for inconvenience and time spent’.
The guideline also details acceptable and unacceptable
recompense, remuneration of guardians of incompetent
participants and remuneration in the event of withdrawal from
a study.
The notion of participant remuneration ranges from the
promotion of research as a socially responsible activity, with no
payment at all but rather recognition for the time and effort of
participants,2 to the view that a wage payment model should
be used in which research subjects are paid an hourly wage
based on that of unskilled workers.3
The amount of money that participants should receive for
their participation is therefore highly contentious. A balance
has to be achieved between a rate of payment that is high
enough not to exploit subjects and low enough that it does not
create an irresistible inducement.4 Most ethics committees in
South Africa allow an amount of R50 per visit to be paid for
travel and food expenses incurred by the participant for the
study visit, and some committees prefer that this amount not
be reflected in the patient information leaflet. However, a
recent recommendation by the Medicines Control Council
(MCC) to investigators in South Africa requires that
participants should receive R150 a visit for expenses incurred
in participation in research and that this should be documented
in the patient information leaflet read by the participant before
deciding whether to participate in the research study.
The ethical concerns involved in participant remuneration
have received attention in the international literature, yet
surprisingly little research attention has been paid to this
question in the South African context where research is
frequently and unavoidably conducted on vulnerable
populations. While many researchers have a strong opinion on
the remuneration of study participants, there is little
understanding of how participants themselves perceive
remuneration for research. 
To investigate this issue, we carried out a semi-structured
cross-sectional study among 334 individuals from the Bishop
Lavis and Elsies River communities in the Western Cape who
had participated in two pharmaceutical industry-sponsored
trials of an intranasal flu vaccine during 2001 and 2002. For
their participation in these trials, participants received R50 at
each of three scheduled study visits and an additional R20 for
unscheduled ‘illness’ visits over a 12-month follow-up period.
For this study, individuals were interviewed in their home
language (English or Afrikaans) by an independent researcher
4 - 12 months after completing the vaccine trial. All participants
gave informed consent before being interviewed. Ethical
approval to conduct this study was granted by the Committee
for Pharmaceutical Trials, University of Stellenbosch. 
The mean age of the 334 participants was 68 years (range 60 -
80 years) and the majority were female, with a mean
educational level of Standard 5 (the equivalent of Grade 7). All
the participants received R50 per study visit (R150 altogether),
although several received up to R200 for additional interim
visits. The majority of those interviewed (N = 281, 84%) felt
that the compensation they received for participation in the
trial was adequate, although a minority (N = 36, 11%)
recommended that the compensation per visit be increased to a
median of R100 per visit (range R70 - R200 per visit). In open-
ended questions regarding compensation, participants stated
that they used the money received in a range of ways,
primarily to purchase food for their families, to transport
themselves or a family member to a clinic or hospital, or to
meet cost-of-living expenses generally.
While drawn from a small sample within a particular
community, these results indicate the complexity of a blanket
compensation policy — as is being requested by the MCC —
for participants in biomedical and epidemiological studies. In
this setting, the standard of R50 per visit for three study visits
spread over 12 months was deemed acceptable, yet it is likely
that other communities may have substantially different
standards — some greater, some lesser. And while there are
sometimes concerns regarding the use of cash as compensation,
these participants used their compensation to meet basic needs.
Generally, identifying the most appropriate level of
compensation for participation in a particular study, as well as
what form it should take, is an important and sometimes
daunting task for researchers. The establishment of a single
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national guideline to be applied across all types of research
throughout the country may be difficult. However, current
literature suggests that research ethics committees should have
written policies on participant remuneration and that these
should be prorated and contextualised to the research
population in question.5
In general, health research ethics guidelines regard the issues
of participant remuneration as residing fairly in the domain of
the research ethics committee involved. In South Africa,
however, a regulatory agency, namely the MCC, has decided to
take this matter unilaterally into its domain. Is it the mandate
of the MCC to review the patient information leaflet and
informed consent documents, especially where participant
remuneration is concerned, or is this a role of the local ethics
committee? Participant remuneration in South Africa — how
much is enough, and who should decide?
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To the Editor: Dating of pregnancy relies traditionally on the
menstrual history using Naegele’s rule, and on uterine sizing.
Uterine sizing is fraught with inconsistency.1 Globally, the last
menstrual period (LMP) date is uncertain or unknown in the
case of at least 20% of pregnant women.2 This seems especially
true in developing countries where more women are more
likely to be uncertain about the LMP and more likely to be late
attendees for antenatal care. 3 It has, however, been postulated
that women booking early for antenatal care have a more
accurate recall of the LMP.4
In view of the uncertainty of both the menstrual history and
the clinical assessment of uterine size, the sonographic
correction of the error margin between the menstrual history-
established gestational age (MHGA) and the clinical sizing
should be corrected by the ultrasound-established gestational
age (USGA).5 This, however, is hardly feasible in developing
world settings devoid of sonographic facilities. It is, therefore,
important to establish the accuracy of menstrual history in
such settings. This is especially relevant to primary health care
(PHC) facilities providing reproductive health care to antenatal
women and to clients seeking a termination of pregnancy
(TOP).
The aim of this study was to establish the accuracy of
menstrual history in a rural setting using sonography as the
gold standard. In addition, it was investigated whether there
was a difference in the accuracy of the menstrual history
between confirmation of pregnancy (COP) and TOP seekers.
A total of 2 627 women entered the study after having given
verbal consent to participate. The following information was
recorded: age, parity, and menstrual history. Only a precise
date of the first day of the LMPwas considered to compute the
MHGA. A standard deviation of ± 1 week was considered
compatible with the USGA.
Immediately after history taking and abdominal palpation a
trans-abdominal ultrasound was performed using a 3.5 MHz
transducer. The following parameters were used to establish
the USGA: crown-rump length (CRL) up to 12 weeks’
gestation, biparietal diameter (BPD) between 12 and 18 weeks,
and femur length (FL) after 18 weeks.
Statistical evaluation was carried out with Statmate and
Prism Version 2 from GraphPad (GraphPad Software Inc., San
Diego, Calif.). Proportions were compared using 95%
confidence intervals (95% CI), Pearson’s chi-square for
categorical variables, and odds ratio (OR) for association. A p-
value < 0.05 was considered statistically significant.
Results
Of the 2 627 participants, 2 124 (80.9%) sought a TOPand 503
(19.1%) a COP. Among the TOP seekers, 385 (18.1% (95% CI
16.5, 19.8)) were actually not pregnant, and 133 (26.4% (22.7,
30.6)) COPseekers were not pregnant (X2 = 17.8, p < 0.0001; OR
= 1.6 (1.3, 2.1)). The menstrual history was known by 1 486
(70.0% (67.9, 71.9)) COP seekers and by 358 (71.2% (67.0, 75.1))
TOP seekers (X2 = 0.28; p = 0.28, OR = 0.94 (0.76, 1.17)).
More than half of the clients in each group were in the third
decade of life. The proportion of teenagers was significantly
higher among the TOP seekers. Among TOP seekers,
nulliparous and primiparous women predominated. COP
seekers were more likely to be nulliparous.
Accuracy of menstrual history in early pregnancy
